Search
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalPI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]
Synonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDELoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial.
Ademetionine
go.drugbank.com/drugs/DB00118ApprovedInvestigationalNutraceuticalPhysiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. … It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Mixtures: HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE, HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETSİZ ŞİŞETecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022. … [A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002.
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … Pirfenidone is a synthetic pyridone drug.
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationallines of systemic therapy, including a BTK inhibitor. … Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies.
Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- ylIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma. … [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.
Butenafine
go.drugbank.com/drugs/DB01091ApprovedIn particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes. … Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols.
Synonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamineButriptyline
go.drugbank.com/drugs/DB09016ApprovedWithdrawnButriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.